Tuesday, July 7, 2026 | TSX: 24,847 ▲ 0.44% | Gold: $3,342 ▼ 0.19% | BTC: $108,240 ▲ 1.82%
NewsletterAdvertiseAbout
Subscribe Free
Live
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%
Drug Approvals

Drug Approvals

⚛️
Biotech
Health Canada Grants 14 Drug Authorizations in Q2 2026 A Record Quarter
Author · July 3, 2026
💰
Biotech
Lecanemab Approved in Canada for Early Alzheimer’s A Landmark Moment for Neuroscience Investors
Author · July 2, 2026
🏦
Biotech
Canada’s Biosimilar Market Reaches $2.4B as Patent Cliffs Accelerate Generic Competition
Author · July 1, 2026
🔶
Biotech
FDA-Health Canada Collaboration Is Cutting Drug Review Times by 18 Months
Author · June 30, 2026
🏦
Biotech
PMPRB Reforms: Canada’s New Drug Pricing Rules and What They Mean for Biotech Returns
Author · June 28, 2026
💰
Biotech
Five Canadian Oncology Drug Approvals to Watch in H2 2026
Author · June 26, 2026

The Boreal Brief

Canadian markets intelligence delivered every morning before the open. Free.